Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, $Pistol Pete$
Search This Board: 
Last Post: 10/15/2019 5:20:37 PM - Followers: 404 - Board type: Free - Posts Today: 0


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mnkd.proboards.com/  A good forum for discussion on Mankind


MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference 09/26/2019 09:00:00 AM
MNKD News: MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD 09/19/2019 09:00:00 AM
MNKD News: MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference 08/30/2019 09:00:00 AM
MNKD News: Quarterly Report (10-q) 08/07/2019 04:08:59 PM
MNKD News: Current Report Filing (8-k) 08/07/2019 04:05:18 PM
#31569  Sticky Note $MNKD MannKind Presents Positive Afrezza® Clinical Data from $Pistol Pete$ 06/11/19 12:13:03 PM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#31687   Got to make a move soon BluSkies 10/15/19 05:20:37 PM
#31686   The ducks are getting in line.....Just don't know Aloha96707 10/15/19 10:28:54 AM
#31685   Were looking like short interest isnt interested in Profit 10/14/19 09:08:02 PM
#31684   How are we looking, Profit? I got an BluSkies 10/14/19 08:22:38 PM
#31683   The bollinger on my weekly chart says somethings Profit 10/13/19 08:14:17 PM
#31682   A bullish resurgence has been detected. I need BluSkies 10/13/19 05:57:18 PM
#31681   Lets Ride! Profit 10/12/19 06:49:49 PM
#31680   Buckled up. Ready to go BluSkies 10/11/19 10:08:47 AM
#31678   Yawn....ok... I’ll be back tomorrow to see how BluSkies 10/10/19 07:33:09 PM
#31677   Not as excited as I was before. BluSkies 10/09/19 04:12:15 PM
#31676   He doesn't know what he means!!!! Aloha96707 10/08/19 05:51:48 PM
#31675   Thank you for the message regarding MNKD. Not BluSkies 10/08/19 04:08:29 PM
#31674   LOL! Did you notice that the new parkerstar 10/07/19 11:49:36 PM
#31673   Mannkind has got its game on get out Profit 10/06/19 09:38:28 AM
#31672   * * $MNKD Video Chart 10-04-2019 * * ClayTrader 10/04/19 04:55:57 PM
#31671   We like the Jefferson's "we are moving on Hypi 10/04/19 01:24:40 PM
#31670   Nice script numbers! BluSkies 10/04/19 09:23:53 AM
#31669   Scared traders got shook out today that’s no BluSkies 09/27/19 10:03:53 PM
#31668   "BAGHOLDERS can READ'EM and WEEP: NEW SCRIPT NUMBERS: parkerstar 09/27/19 08:23:47 AM
#31667   MannKind Corporation to Present at the 2019 Cantor Golden_Cross 09/26/19 05:02:46 PM
#31666   Setting up to be a monster run here BluSkies 09/26/19 10:06:30 AM
#31665   Lets Go! Profit 09/25/19 06:06:40 PM
#31664   Blue Skies coming imo BluSkies 09/25/19 05:32:38 PM
#31663   Waiting on that Brazil News! BluSkies 09/24/19 10:10:28 AM
#31662   I am thinking so here Blu... RSI getting Golden_Cross 09/23/19 04:10:01 PM
#31661   This ready for launch? BluSkies 09/23/19 03:40:02 PM
#31660   Technical "BUY" Signal For 9-21 $MNKD Golden_Cross 09/21/19 06:00:56 PM
#31659   MNKD Daily Chart Golden_Cross 09/21/19 05:58:26 PM
#31658   Why don't you compare numbers from the same Aloha96707 09/21/19 01:20:39 AM
#31657   Really? Where? I looked all over and couldn't parkerstar 09/20/19 08:56:19 AM
#31656   "Like watching PAINT dry -- NEW SCRIPT NUMBERS: parkerstar 09/20/19 08:39:05 AM
#31655   US Professional Healthcare website updated on 9/11/19 lists Hypi 09/19/19 12:27:48 AM
#31654   "NDA has already been filed by UTHR for parkerstar 09/18/19 10:50:38 AM
#31653   NDA has already been filed by UTHR for Hypi 09/17/19 12:50:13 PM
#31652   Well, FIRST, it's "TreT" and NOT "trept." parkerstar 09/17/19 09:01:58 AM
#31651   Really???? Seems like desperation to me!! Aloha96707 09/17/19 12:56:41 AM
#31650   So wrong as LQDA stock has dropped from Hypi 09/16/19 01:13:48 PM
#31649   You DO understand that trevyent is an external parkerstar 09/16/19 11:36:11 AM
#31648   How am I wrong? This main article was Aloha96707 09/16/19 12:19:11 AM
#31647   You are wrong. By the way scrips will Hypi 09/15/19 08:45:20 PM
#31646   MNKD Daily Chart Golden_Cross 09/14/19 04:59:29 AM
#31645   Lets Go! Profit 09/13/19 09:57:21 PM
#31644   mnkd Profit 09/13/19 07:45:25 PM
#31643   Wow looking great kugel 09/13/19 05:11:17 PM
#31642   "Time for MNKD investor wailing and gnashing of parkerstar 09/13/19 07:15:37 AM
#31641   Looks like short interest has not budged, but Profit 09/13/19 02:39:56 AM
#31640   Closed a cent down. Definitely getting started lol SidVicious 09/13/19 01:19:19 AM
#31639   Yep...but pumpers don’t care SidVicious 09/13/19 01:18:15 AM
#31638   This has nothing to do with MNKD. Aloha96707 09/12/19 07:13:27 PM
#31637   https://finance.yahoo.com/news/united-therapeutics-trevyent-nda-pah-152503054.ht Hypi 09/12/19 02:34:21 PM